Shortages of commonly used drugs are causing concerns for pharmacists and patients across Canada. The shortage of Lenoltec No. 4, a generic version of Tylenol 4, and Ozempic, a drug for Type 2 diabetes, has been ongoing for several months and is not expected to be resolved until the new year. The shortage is impacting pharmacies and patients nationwide, although certain areas may experience more significant shortages than others. The shortage is due to factors such as disruptions in drug manufacturing and increased demand.
Pharmacists are facing challenges in meeting the demand for these essential medications. The shortage of Lenoltec No. 4, in particular, has been ongoing since April 19, 2023, according to Canada’s drug shortage database. The pharmaceutical company Teva Canada estimates that the shortage will last until January 10, 2024. The shortage of Ozempic, on the other hand, is expected to be resolved by March 21, 2024, according to the drug shortage database. The limited supply of Ozempic is attributed to a manufacturing shortage of the plastic used to make the injection pens for the drug.
The shortage of these medications is not limited to Edmonton or Alberta, but is a nationwide issue. Health Canada works with manufacturers to import drugs from other countries in order to help fill the supply gap. However, finding suitable alternatives for these medications can be challenging. Lenoltec No. 4 can be replaced with equivalent dosages of acetaminophen and codeine, although it may be less convenient for patients to take multiple tablets instead of one. The shortage of Ozempic poses a greater concern, as there are not many alternatives available, and the substitutes may not be covered by government assistance programs.
The shortage of these drugs is expected to persist for several more months, despite manufacturer estimates for when the shortages will be resolved. Pharmacists are working to manage the shortages and find solutions for their patients. However, the ongoing drug shortages have become a new reality in Canada, with various factors contributing to the problem. It is important for patients to communicate with their pharmacists and physicians about any concerns regarding the drug supply and to avoid hoarding medications. Supplies are expected to become available again in the future.
In conclusion, the shortage of commonly used drugs in Canada is causing challenges for pharmacists and patients. The ongoing shortages of Lenoltec No. 4 and Ozempic are expected to last until at least the new year. It is important for patients to work with their healthcare providers to find suitable alternatives and to avoid hoarding medications.